Sclerostin Immunoreactivity Increases in Cortical Bone Osteocytes and Decreases in Articular Cartilage Chondrocytes in Aging Mice

Michelle L. Thompson, Juan Miguel Jimenez-Andrade, Patrick W Mantyh

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Sclerostin is a 24-kDa secreted glycoprotein that has been identified as a negative modulator of new bone formation and may play a major role in age-related decline in skeletal function. Although serum levels of sclerostin markedly increase with age, relatively little is known about whether cells in the skeleton change their expression of sclerostin with aging. Using immunohistochemistry and confocal microscopy, we explored sclerostin immunoreactivity (sclerostin-IR) in the femurs of 4-, 9-, and 24-month-old adult C3H/HeJ male mice. In the femur, the only two cell types that expressed detectable levels of sclerostin-IR were bone osteocytes and articular cartilage chondrocytes. At three different sites along the diaphysis of the femur, only a subset of osteocytes expressed sclerostin-IR and the percentage of osteocytes that expressed sclerostin-IR increased from approximately 36% to 48% in 4- vs. 24-month-old mice. In marked contrast, in the same femurs, there were ~40% fewer hypertrophic chondrocytes of articular cartilage that expressed sclerostin-IR when comparing 24- vs. 4-month-old mice. Understanding the mechanism(s) that drive these divergent changes in sclerostin-IR may provide insight into understanding and treating the age-related decline of the skeleton.

Original languageEnglish (US)
Pages (from-to)179-189
Number of pages11
JournalJournal of Histochemistry and Cytochemistry
Volume64
Issue number3
DOIs
StatePublished - Mar 1 2016

Fingerprint

Osteocytes
Articular Cartilage
Chondrocytes
Femur
Skeleton
Diaphyses
Osteogenesis
Confocal Microscopy
Glycoproteins
Immunohistochemistry
Bone and Bones
Cortical Bone
Serum

Keywords

  • aged
  • articular cartilage
  • cortical bone
  • hypertrophic chondrocyte
  • joint
  • osteocyte subtype

ASJC Scopus subject areas

  • Anatomy
  • Histology

Cite this

Sclerostin Immunoreactivity Increases in Cortical Bone Osteocytes and Decreases in Articular Cartilage Chondrocytes in Aging Mice. / Thompson, Michelle L.; Jimenez-Andrade, Juan Miguel; Mantyh, Patrick W.

In: Journal of Histochemistry and Cytochemistry, Vol. 64, No. 3, 01.03.2016, p. 179-189.

Research output: Contribution to journalArticle

@article{33c0ee4ae3ac49c7995d3dec9a874ad0,
title = "Sclerostin Immunoreactivity Increases in Cortical Bone Osteocytes and Decreases in Articular Cartilage Chondrocytes in Aging Mice",
abstract = "Sclerostin is a 24-kDa secreted glycoprotein that has been identified as a negative modulator of new bone formation and may play a major role in age-related decline in skeletal function. Although serum levels of sclerostin markedly increase with age, relatively little is known about whether cells in the skeleton change their expression of sclerostin with aging. Using immunohistochemistry and confocal microscopy, we explored sclerostin immunoreactivity (sclerostin-IR) in the femurs of 4-, 9-, and 24-month-old adult C3H/HeJ male mice. In the femur, the only two cell types that expressed detectable levels of sclerostin-IR were bone osteocytes and articular cartilage chondrocytes. At three different sites along the diaphysis of the femur, only a subset of osteocytes expressed sclerostin-IR and the percentage of osteocytes that expressed sclerostin-IR increased from approximately 36{\%} to 48{\%} in 4- vs. 24-month-old mice. In marked contrast, in the same femurs, there were ~40{\%} fewer hypertrophic chondrocytes of articular cartilage that expressed sclerostin-IR when comparing 24- vs. 4-month-old mice. Understanding the mechanism(s) that drive these divergent changes in sclerostin-IR may provide insight into understanding and treating the age-related decline of the skeleton.",
keywords = "aged, articular cartilage, cortical bone, hypertrophic chondrocyte, joint, osteocyte subtype",
author = "Thompson, {Michelle L.} and Jimenez-Andrade, {Juan Miguel} and Mantyh, {Patrick W}",
year = "2016",
month = "3",
day = "1",
doi = "10.1369/0022155415626499",
language = "English (US)",
volume = "64",
pages = "179--189",
journal = "Journal of Histochemistry and Cytochemistry",
issn = "0022-1554",
publisher = "Histochemical Society Inc.",
number = "3",

}

TY - JOUR

T1 - Sclerostin Immunoreactivity Increases in Cortical Bone Osteocytes and Decreases in Articular Cartilage Chondrocytes in Aging Mice

AU - Thompson, Michelle L.

AU - Jimenez-Andrade, Juan Miguel

AU - Mantyh, Patrick W

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Sclerostin is a 24-kDa secreted glycoprotein that has been identified as a negative modulator of new bone formation and may play a major role in age-related decline in skeletal function. Although serum levels of sclerostin markedly increase with age, relatively little is known about whether cells in the skeleton change their expression of sclerostin with aging. Using immunohistochemistry and confocal microscopy, we explored sclerostin immunoreactivity (sclerostin-IR) in the femurs of 4-, 9-, and 24-month-old adult C3H/HeJ male mice. In the femur, the only two cell types that expressed detectable levels of sclerostin-IR were bone osteocytes and articular cartilage chondrocytes. At three different sites along the diaphysis of the femur, only a subset of osteocytes expressed sclerostin-IR and the percentage of osteocytes that expressed sclerostin-IR increased from approximately 36% to 48% in 4- vs. 24-month-old mice. In marked contrast, in the same femurs, there were ~40% fewer hypertrophic chondrocytes of articular cartilage that expressed sclerostin-IR when comparing 24- vs. 4-month-old mice. Understanding the mechanism(s) that drive these divergent changes in sclerostin-IR may provide insight into understanding and treating the age-related decline of the skeleton.

AB - Sclerostin is a 24-kDa secreted glycoprotein that has been identified as a negative modulator of new bone formation and may play a major role in age-related decline in skeletal function. Although serum levels of sclerostin markedly increase with age, relatively little is known about whether cells in the skeleton change their expression of sclerostin with aging. Using immunohistochemistry and confocal microscopy, we explored sclerostin immunoreactivity (sclerostin-IR) in the femurs of 4-, 9-, and 24-month-old adult C3H/HeJ male mice. In the femur, the only two cell types that expressed detectable levels of sclerostin-IR were bone osteocytes and articular cartilage chondrocytes. At three different sites along the diaphysis of the femur, only a subset of osteocytes expressed sclerostin-IR and the percentage of osteocytes that expressed sclerostin-IR increased from approximately 36% to 48% in 4- vs. 24-month-old mice. In marked contrast, in the same femurs, there were ~40% fewer hypertrophic chondrocytes of articular cartilage that expressed sclerostin-IR when comparing 24- vs. 4-month-old mice. Understanding the mechanism(s) that drive these divergent changes in sclerostin-IR may provide insight into understanding and treating the age-related decline of the skeleton.

KW - aged

KW - articular cartilage

KW - cortical bone

KW - hypertrophic chondrocyte

KW - joint

KW - osteocyte subtype

UR - http://www.scopus.com/inward/record.url?scp=84959342427&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959342427&partnerID=8YFLogxK

U2 - 10.1369/0022155415626499

DO - 10.1369/0022155415626499

M3 - Article

C2 - 26701970

AN - SCOPUS:84959342427

VL - 64

SP - 179

EP - 189

JO - Journal of Histochemistry and Cytochemistry

JF - Journal of Histochemistry and Cytochemistry

SN - 0022-1554

IS - 3

ER -